CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
July 2017—Agena Bioscience introduced targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSeek Lung and Colon Panels enable the detection of mutations as low as 0.1 percent minor allele frequency from circulating tumor cells and circulating tumor DNA. The iPlex HS Lung and Colon Panels enable detection of mutations as low as one percent MAF from solid tumor tissue.
The highly multiplexed panels target mutations of known significance in BRAF, EGFR, ERBB2, KRAS, NRAS, and PIK3CA genes, and can work with DNA extracted from a single 10 mL blood draw. With high detection sensitivity and broad coverage, the panels offer a complete solution, from initial stratification to monitoring disease progression. The panels, for use on the MassArray System, are commercially available worldwide.
Agena Bioscience, 858-882-2800